The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent

NA Moore, NC Tye, MS Axton and FC Risius

Lilly Research Centre, Eli Lilly and Co., Windlesham, Surrey, United Kingdom.

Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H- thieno[2,3-b][1,5] benzodiazepine) is a novel "atypical" antipsychotic agent with 5-hydroxytryptamine2.dopamine D1/D2 antagonist activity and anticholinergic properties. In behavioral studies, olanzapine (1.25-10 mg/kg, p.o.) antagonizes apomorphine-induced climbing behavior in mice, demonstrating that the compound possesses D1/D2 antagonist activity in vivo. Olanzapine (0.3-20 mg/kg, p.o.) antagonizes 5-hydroxytryptophan- induced head twitches in mice at doses much lower than those required to block the climbing response, confirming that in vivo, the compound is a more potent 5-hydroxytryptamine2 antagonist than dopamine antagonist. Olanzapine (2.5-10 mg/kg, p.o.) also antagonized oxotremorine-induced tremor in mice. In a conditioned avoidance paradigm in rats, olanzapine inhibits the avoidance response with an ED50 of 4.7 mg/kg p.o; however, unlike other antipsychotic agents, catalepsy is only observed at much higher doses (ED50 39.4 mg/kg, p.o.). These data would suggest that the compound will be less likely to produce undesirable extrapyramidal symptoms. Unlike "typical" antipsychotics, olanzapine (1.25-5 mg/kg p.o.) increases responding during the conflict component of a modified Geller Seifter test, demonstrating that the compound may also possess anxiolytic activity. In another series of experiments, olanzapine (1.25 mg/kg, i.p.) produced clozapine-appropriate responding in a drug discrimination model in which animals had been trained to discriminate clozapine (5 mg/kg, i.p.) from vehicle. On the basis of these results, it would therefore be predicted that olanzapine will have an atypical profile and will be less likely to induce undesirable extrapyramidal symptoms than currently available drugs.

Volume 262, Issue 2, pp. 545-551, 08/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. K. Jones, A. E. Brady, A. A. Davis, Z. Xiang, M. Bubser, M. N. Tantawy, A. S. Kane, T. M. Bridges, J. P. Kennedy, S. R. Bradley, et al. Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats J. Neurosci., October 8, 2008; 28(41): 10422 - 10433. [Abstract] [Full Text] [PDF]

				K. Rasmussen, M.-A. Hsu, S. Noone, B. G. Johnson, L. K. Thompson, and S. K. Hemrick-Luecke The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms Schizophr Bull, November 1, 2007; 33(6): 1291 - 1297. [Abstract] [Full Text] [PDF]

				A. J. Goudie, G. D. Cooper, J. C. Cole, and H. R. Sumnall Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J Psychopharmacol, March 1, 2007; 21(2): 179 - 190. [Abstract] [PDF]

				H. E. Shannon, J. C. Hart, F. P. Bymaster, D. O. Calligaro, N. W. DeLapp, C. H. Mitch, J. S. Ward, A. Fink-Jensen, P. Sauerberg, L. Jeppesen, et al. Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 901 - 907. [Abstract] [Full Text]

				M. J. Millan, R. Schreiber, S. Monneyron, B. Denorme, C. Melon, S. Queriaux, and A. Dekeyne S-16924, a Novel, Potential Antipsychotic with Marked Serotonin1A Agonist Properties. IV. A Drug Discrimination Comparison with Clozapine J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 427 - 436. [Abstract] [Full Text]

				T. M. Sanger, J. A. Lieberman, M. Tohen, S. Grundy, C. Beasley Jr., and G. D. Tollefson Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis Am J Psychiatry, January 1, 1999; 156(1): 79 - 87. [Abstract] [Full Text]

				C. Cohen, D. J. Sanger, and G. Perrault Characterization of the Discriminative Stimulus Produced by the Dopamine Antagonist Tiapride J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 566 - 573. [Abstract] [Full Text]

				C. Debattista, B. Solvason, J. Belanoff, and A. F. Schatzberg Treatment of Psychotic Depression Am J Psychiatry, November 1, 1997; 154(11): 1625 - 1626. [Full Text]

				E. Mattiuz, R. Franklin, T. Gillespie, A. Murphy, J. Bernstein, A. Chiu, T. Hotten, and K. Kassahun Disposition and Metabolism of Olanzapine in Mice, Dogs, and Rhesus Monkeys Drug Metab. Dispos., May 1, 1997; 25(5): 573 - 583. [Abstract] [Full Text]

				A. H. Tang, S. R. Franklin, C. S. Himes, M. W. Smith, and R. E. Tenbrink PNU-96415E, a Potential Antipsychotic Agent with Clozapine-Like Pharmacological Properties J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 440 - 447. [Abstract] [Full Text]

				K. Kassahun, E. Mattiuz, E. Nyhart Jr., B. Obermeyer, T. Gillespie, A. Murphy, R. M. Goodwin, D. Tupper, J. T. Callaghan, and L. Lemberger Disposition and Biotransformation of the Antipsychotic Agent Olanzapine in Humans Drug Metab. Dispos., January 1, 1997; 25(1): 81 - 93. [Abstract] [Full Text]

				N. A. Moore Is the 'A' in atypical really due to {alpha}2-adrenoceptor antagonism? A comment on: Putting the 'A' in atypical: does {alpha}2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol, January 1, 1995; 9(2): 155 - 155. [PDF]